Bristol Myers Squibb (BMY) stock is in focus after the company's weak outlook overshadowed its earnings beat. However, the ...

Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

Recent health news includes Bristol Myers' projected revenue dip due to generic competition and cost cuts, Trump's tariffs ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday. The Dow ...

By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...